BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in constitutive activation of AKT, which leads to up-regulation of mammalian target of rapamycin (mTOR). Everolimus is an oral rapamycin analog that acts by selectively inhibiting mTOR. METHODS: A single-institution, open-labeled, phase 2 study of everolimus in patients with measurable recurrent EC who had failed at least 1 and no more than 2 prior chemotherapeutic regimens was performed. Everolimus was administered at a dose of 10 mg orally daily for 28-day cycles. Patients were treated until disease progression or toxicity. The primary endpoint was clinical benefit response (CBR), defined as a confirmed complete or partial response or prolonged stable disease (SD) (≥8 weeks). Inclusion was limited to patients with endometrioid histology. RESULTS: A total of 35 patients were enrolled (median age, 58 years; range, 38-81 years). A total of 81 cycles were administered. Twelve of 28 (43%) evaluable patients had not developed disease progression at the time of the first objective evaluation (8 weeks). All these patients had SD (median, 4.5 cycles; range, 2-10 cycles). Six of the 28 (21%) patients had a confirmed CBR at 20 weeks of therapy. Patients with CBR discontinued treatment because of toxicity (6 patients), disease progression (5 patients), and noncompliance (1 patient). Seven patients were unevaluable after receiving ≤1 cycle because of toxicity (5 patients) or noncompliance (2 patients). The most common drug-related toxicities were fatigue, anemia, pain, lymphopenia, and nausea. CONCLUSIONS: Everolimus demonstrated encouraging single-agent CBR in pretreated patients with recurrent endometrioid EC. Future studies will evaluate this agent in combination with hormonal and/or cytotoxic therapy.
BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in constitutive activation of AKT, which leads to up-regulation of mammalian target of rapamycin (mTOR). Everolimus is an oral rapamycin analog that acts by selectively inhibiting mTOR. METHODS: A single-institution, open-labeled, phase 2 study of everolimus in patients with measurable recurrent EC who had failed at least 1 and no more than 2 prior chemotherapeutic regimens was performed. Everolimus was administered at a dose of 10 mg orally daily for 28-day cycles. Patients were treated until disease progression or toxicity. The primary endpoint was clinical benefit response (CBR), defined as a confirmed complete or partial response or prolonged stable disease (SD) (≥8 weeks). Inclusion was limited to patients with endometrioid histology. RESULTS: A total of 35 patients were enrolled (median age, 58 years; range, 38-81 years). A total of 81 cycles were administered. Twelve of 28 (43%) evaluable patients had not developed disease progression at the time of the first objective evaluation (8 weeks). All these patients had SD (median, 4.5 cycles; range, 2-10 cycles). Six of the 28 (21%) patients had a confirmed CBR at 20 weeks of therapy. Patients with CBR discontinued treatment because of toxicity (6 patients), disease progression (5 patients), and noncompliance (1 patient). Seven patients were unevaluable after receiving ≤1 cycle because of toxicity (5 patients) or noncompliance (2 patients). The most common drug-related toxicities were fatigue, anemia, pain, lymphopenia, and nausea. CONCLUSIONS:Everolimus demonstrated encouraging single-agent CBR in pretreated patients with recurrent endometrioid EC. Future studies will evaluate this agent in combination with hormonal and/or cytotoxic therapy.
Authors: S Ramaswamy; N Nakamura; F Vazquez; D B Batt; S Perera; T M Roberts; W R Sellers Journal: Proc Natl Acad Sci U S A Date: 1999-03-02 Impact factor: 11.205
Authors: Y Kanamori; J Kigawa; H Itamochi; M Shimada; M Takahashi; S Kamazawa; S Sato; R Akeshima; N Terakawa Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: K Podsypanina; R T Lee; C Politis; I Hennessy; A Crane; J Puc; M Neshat; H Wang; L Yang; J Gibbons; P Frost; V Dreisbach; J Blenis; Z Gaciong; P Fisher; C Sawyers; L Hedrick-Ellenson; R Parsons Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: José Baselga; Vladimir Semiglazov; Peter van Dam; Alexey Manikhas; Meritxell Bellet; José Mayordomo; Mario Campone; Ernst Kubista; Richard Greil; Giulia Bianchi; Jutta Steinseifer; Betty Molloy; Erika Tokaji; Humphrey Gardner; Penny Phillips; Michael Stumm; Heidi A Lane; J Michael Dixon; Walter Jonat; Hope S Rugo Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544
Authors: Helga B Salvesen; Ingunn Stefansson; Ellen I Kretzschmar; Paula Gruber; Nicola D MacDonald; Andy Ryan; Ian J Jacobs; Lars A Akslen; Soma Das Journal: Int J Oncol Date: 2004-12 Impact factor: 5.650
Authors: Michael R Milam; Joseph Celestino; Weiguo Wu; Russell R Broaddus; Kathleen M Schmeler; Brian M Slomovitz; Pamela T Soliman; David M Gershenson; Hong Wang; Lora H Ellenson; Karen H Lu Journal: Am J Obstet Gynecol Date: 2007-03 Impact factor: 8.661
Authors: Larissa A Meyer; Brian M Slomovitz; Bojana Djordjevic; Shannon N Westin; David A Iglesias; Mark F Munsell; Yunyun Jiang; Rosemarie Schmandt; Russell R Broaddus; Robert L Coleman; John M Galbincea; Karen H Lu Journal: Int J Gynecol Cancer Date: 2014-05 Impact factor: 3.437
Authors: A S McCampbell; M L Mittelstadt; R Dere; S Kim; L Zhou; B Djordjevic; P T Soliman; Q Zhang; C Wei; S D Hursting; K H Lu; R R Broaddus; C L Walker Journal: Curr Mol Med Date: 2016 Impact factor: 2.222
Authors: Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie Journal: Gynecol Oncol Date: 2014-01-20 Impact factor: 5.482
Authors: Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao Journal: Cancer Res Date: 2013-12-09 Impact factor: 12.701